High Cardiovascular Inflammation Found in U.S. Patients

A new registry study reveals elevated inflammatory markers in nearly half of American heart failure patients.

Updated on Oct. 14, 2026 in Heart Disease

High Cardiovascular Inflammation Found in U.S. Patients

Live Poll

Do you trust that current medical research effectively addresses heart inflammation in patients?

A cross-sectional analysis of the POSEIDON registry has identified that roughly half of heart failure patients in the United States exhibit elevated high-sensitivity C-reactive protein (hsCRP) levels. These markers of cardiovascular inflammation were observed across various types of heart failure diagnoses.

Why it matters

Identifying high inflammation prevalence helps researchers evaluate the need for targeted anti-inflammatory pharmacotherapy in heart failure populations. These findings clarify the link between inflammatory markers and underlying health conditions like obesity, diabetes, and kidney disease.

The POSEIDON registry enrolled 18,904 adults globally, including 801 total participants in the U.S. subset. Elevated hsCRP levels in these patients are positively correlated with increased IL-6 and NT-proBNP concentrations.

The players

Novo Nordisk

This pharmaceutical company is a global leader in diabetes and obesity care that develops various cardiovascular and metabolic therapies.

Heart Failure Society

This professional organization supports clinicians and researchers dedicated to advancing the care and treatment of patients with heart failure.

The details

Researchers utilized hsCRP measurements to gauge systemic inflammation across different heart failure classifications. The study highlights that U.S. patients consistently show higher inflammatory prevalence than the global average across all observed categories.

Participants were recruited for the POSEIDON study between 2023 and 2025.
Novo Nordisk stopped the HERMES and ATHENA trials in September 2026.
The registry findings were presented at a Heart Failure Society conference in October 2026.

Health Landscape

The use of the POSEIDON registry allows researchers to benchmark American health data against global trends, highlighting regional differences in patient inflammation. This data is critical for shaping the next generation of targeted cardiovascular treatments as existing drug trials face setbacks.

Patients with heart failure may consult their doctors about the significance of hsCRP testing to monitor their cardiovascular inflammatory status. Understanding these markers can assist healthcare providers in managing underlying conditions like diabetes and kidney disease that drive systemic inflammation.

The takeaway

Clinicians are increasingly using inflammatory markers like hsCRP to identify high-risk patients who may benefit from future pharmacological interventions. Maintaining healthy levels through the management of obesity and diabetes remains a foundational strategy for reducing cardiovascular stress.